News 2023-09-28
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia.
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia. PCS programs are designed to stimulate in-depth discussions on common and/or leading bottleneck issues related to crystallization of drug substance (DS) as well as the intermediates, the technologies and solutions that are available or underdevelopment. The discussions help new medicine developers to make educated and phase-appropriate decisions, and crystallization experts to understand better the critical needs for providing effective solutions.
The Pharma Crystallization Summit (PCS) has been serving effectively for bridging the gap between drug substance (DS) and drug product (DP) developments. PCS 2023 will be held on October 5 – 6 at New Jersey Institute of Technology (NJIT), Newark, NJ, USA. Extending from the valued topics in the past, this 4th PCS will focus on the following topics:
Session I: Enabling Greener DS Synthetics Routes
Session II: Enabling Desired DS Quality Attributes
Session III: Enabling Improved DP Performance
Panel Discussion Topics:
1) Crystallization challenges and dream solutions supporting synthetic route optimization
2) API isolation challenges and better solutions to ensure robust production
3) Addressing formulation challenges via particle engineering and co-processing
End of Summit & See you in 2024!
Others
More
News 2026-09-17
Porton Congratulates Partner Acepodia on FDA and NMPA IND Approvals for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.
News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
